Clinical Trial Update: Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial) [Phase 2]

View source ↗

Summary

A Phase 2 RAMA-Trial evaluating ranibizumab for macular telangiectasia type 2 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Telangiectasia Type

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: University Hospital, Bonn | Conditions: Type 2 Idiopathic Macular Telangiectasia | Phase 2 | Status: COMPLETED